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Abstract	
BACKGROUND	&	AIMS:	Genome-wide association studies (GWAS) have identified 200 
inflammatory bowel disease (IBD) loci, but the genetic architecture of Crohn’s disease (CD) 
and ulcerative colitis (UC) remains incompletely defined. Here we aimed to identify novel 
associations between IBD and functional genetic variants using the Illumina ExomeChip. 
METHODS:	Genotyping was performed in 10,523 IBD cases and 5,726 non-IBD controls. 
91,713 functional single nucleotide polymorphism (SNP) loci in coding regions were 
analyzed. A novel identified association was further replicated in two independent cohorts. 
We further examined the association of the identified SNP with microbiota from 338 
mucosal lavage samples in the Mucosal Luminal Interface (MLI) cohort measured using 16S 
sequencing. RESULTS:	We identified an association between CD and a missense variant 
encoding alanine (Ala) or threonine (Thr) at position 391 in the zinc transporter solute 
carrier family 39, member 8 protein (SLC39A8 Ala391Thr, rs13107325) and replicated the 
association with CD in two replication cohorts (combined meta-analysis p=5.55x10-13). 
This variant has previously been associated with distinct phenotypes including obesity, 
lipid levels, blood pressure and schizophrenia. We subsequently determined that the CD-
risk allele was associated with altered colonic mucosal microbiome composition in both 
healthy controls (p=0.009) and CD cases (p=0.0009). Moreover, microbes depleted in 
healthy carriers strongly overlap with those reduced in CD patients (p=9.24x10-16) and 
overweight individuals (p=6.73x10-16). CONCLUSIONS:	Our results suggest that an 
SLC39A8-dependent shift in the gut microbiome could explain its pleiotropic effects on 
multiple complex diseases including CD. 
Keywords:  Genetics; Inflammatory Bowel Diseases; Microbiota 
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Introduction	
The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), 
are chronic relapsing inflammatory conditions of the  gastrointestinal tract.1 These diseases 
are a significant cause of morbidity and have estimated direct and indirect costs of $6 
billion annually in the United States.2 
Currently, the etiology and pathogenesis of IBD are not fully understood, but it is widely 
accepted that genetic factors play an important role. Common variant genome-wide 
association studies have identified 200 IBD-associated loci.3, 4 However, these loci explain 
only part of the variance and genetic architecture of CD and UC.3, 4 
Changes in the gut microbiota have also been associated with IBD.5-11 IBD patients have 
reduced bacterial diversity, and complex compositional changes in CD or UC patients 
include increased Enterobacteriaceae (such as E. coli) and Veillonellacae, and reduced 
Ruminococcaceae (such as F. prauznitzii), Roseburia, and Clostridiales. Moreover, many of 
the known IBD susceptibility genes are associated with recognition and processing of 
bacteria.3, 4, 12-14 A ‘gardening’ effect of known IBD genetic variants on gut microbiome has 
also been reported, suggesting a role of the gut microbiota in the pathogenesis of IBD.15 
In this study, we aimed to identify novel associations between IBD and functional genetic 
variants using the Illumina ExomeChip array in a large European ancestry cohort. We also 
examined the microbiome shift associated with an identified novel locus to elucidate its 
functional role and understand how it contributes to disease pathogenesis. 
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Materials	and	Methods	
Overview	
A collaborative group with a shared goal of conducting cost-effective genotyping of their 
case samples and shared control samples using the Illumina Infinium HumanExome 
BeadChip was formed. The HumanExome BeadChip was designed to complement common 
variant genotyping arrays by enabling cost-effective genotyping of putative functional 
exonic variants that were selected from over 12,000 individual exome and whole-genome 
sequences from diverse populations. Its content includes non-synonymous variants, splice 
variants, and stop altering variants, observed at least two times across two or more of the 
sequencing datasets. It also includes: tags for previously described GWAS hits; African 
American vs. European and Native American vs. European ancestry informative markers; a 
scaffold grid of markers designed for identity by descent analyses; a random set of 
synonymous variants; fingerprint SNPs shared among several major genotyping platforms; 
mitochondrial SNPs; chromosome Y SNPs; and HLA tag SNPs. Some of the collaborating 
groups designed custom content that was added to the HumanExome base content to 
address individual project-specific aims. The resultant Illumina Infinium HumanExome+ 
BeadChip was used to genotype all cases and shared control samples. Written, informed 
consent was obtained from all study participants and the institutional ethical review 
committees of the participating centers approved all protocols. 
The data for all samples were pooled together in order to optimize accurate genotype 
calling and quality control filtering. In this manuscript, we report results from our analyses 
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of predicted functional SNPs (missense, nonsense or splice variants) in non-Jewish 
European ancestry IBD case and control samples. 
Illumina	Infinium	HumanExome+	BeadChip	genotyping	and	quality	control	
DNA samples from 23,789 human peripheral blood or B-lymphoblastoid cell line specimens 
were processed using an Illumina Infinium HumanExome+ BeadChip at Cedars-Sinai 
Medical Center in Los Angeles, California; The Children’s Hospital of Philadelphia in 
Philadelphia, Pennsylvania; The Feinstein Institute for Medical Research in Manhasset, 
New York; and the University of Pittsburgh in Pittsburgh, Pennsylvania. A single compiled 
genotyping project was created (GenomeStudio v2011.1) and intensity data for 21,233 
samples deemed to be the highest quality samples based on preliminary genotype call rate 
and p10GC statistics were used to recluster all SNPs, and then the resultant cluster file was 
applied to all samples. Variants were then systematically reviewed based on several 
marker statistic parameters including cluster separation, theta mean and deviation, 
heterozygous excess and frequency, call frequency, minor allele frequency, R intensity 
mean, and replicate error rate, in addition to review of mitochondrial and Y chromosome 
markers and indels.16 Following these quality control metrics, 6,849 SNPs were excluded 
without further manual review and 48,962 SNPs were manually reviewed and when 
possible, cluster locations adjusted to achieve optimal allele-calling. There was 99.9963% 
concordance for genotypes in 273 replicate control samples. 
After genotype calling was complete, 1,161 samples were excluded based on the following 
criteria: p10GC and call rate statistics, gender discrepancies between reported and 
genotype-determined gender or ambiguous genotype-determined gender, misidentified 
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samples, outlier samples consistently clustering outside the three distinct genotype 
clusters as identified by manual review of intensity data plots, high heterozygosity, and 
genetic relatedness. After the genotype calling and quality control filtering steps, data for 
207,625 polymorphic SNP assays in 22,628 individuals remained. 
We focused our subsequent analyses on 10,523 IBD cases (5,742 CD, 4,583 UC and 198 IBD 
unclassified) and 5,726 controls that formed a major European ancestry cluster based on 
principal components analyses, and on 153,486 autosomal and chromosome X SNPs 
predicted to be functional (missense, nonsense or splice variants) and available in the 
HumanExome base content with ≤0.5% missing data and Hardy-Weinberg equilibrium p-
value in controls ≥1×10-5. 
Statistical	analyses	
We adopted strategies previously utilized for ExomeChip single SNP analysis17. SNPs with 
at least 6 copies of minor alleles observed in the sample set were included in the single SNP 
analysis, and 61,773 SNPs with less than 6 copies were excluded. For the 91,713 variants 
included in the single SNPs analysis, the significance threshold was 5.45x10-7 after 
Bonferroni correction. To account for the rare variants in single SNP analysis, statistical 
inference on trait-SNP association was performed using linear regression assuming an 
additive genetic model, following examples in a previous study.17 In single SNP analysis, we 
also utilized logistic regression to estimate the Odds ratios (OR) and 95% confidence 
intervals (95% CI) when applicable. The first four principle components were included in 
the model as covariates to control for potential confounding effects due to population 
stratification. In addition to the standard genotyping quality control measures (listed 
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above), genotype clusters for key SNPs listed in main tables were manually reviewed by 
two independent research personnel to ensure accurate allele-calling. 
Replication	cohorts	
To validate novel association findings, we used two additional cohorts, including non-
overlapping samples from a pediatric IBD GWAS cohort (1,096 CD cases and 6,088 non-IBD 
controls)18 and the Prospective Registry in IBD Study at Massachusetts General Hospital 
(PRISM) exome chip cohort (551 CD cases and 2,344 non-IBD controls).19 In both cohorts, 
association was tested using logistic regression with adjustment for principal components. 
We also performed an inverse-variance meta-analysis to combine results from all three 
cohorts, leading to a total sample size of 7,389 cases and 14,158 controls. 
Microbiome	analysis	
The MLI cohort consists of 338 mucosal lavage samples from the cecum and sigmoid colon 
(i.e. 2 samples per person) of healthy individuals (22 SLC39A8 Thr391 allele carriers and 
75 non-carriers) and CD patients in endoscopic remission (16 SLC39A8 Thr391 allele 
carriers and 58 non-carriers).20 Genomic DNA extraction, V4 region 16S ribosomal RNA 
gene amplification, data-preprocessing, and 97% operational taxonomic unit (OTU) picking 
were performed as previously described,20 yielding a median sampling sequencing depth of 
606,105. Alpha diversity was assessed using the number of observed species, Chao1, 
phylogenetic diversity, and Shannon index on rarefied data. 16S rRNA abundances 
underwent normalization by a scaling factor (median of ratios of OTU counts to geometric 
mean across all samples).21 Distance matrices were calculated using root square Jensen-
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Shannon divergence, and then principal coordinates analysis was performed in QIIME. 
Additional beta diversity metrics including unweighted UniFrac, weighted UniFrac, and 
Bray–Curtis were measured using rarefied data in QIIME. P-values were calculated using 
Adonis. 
Analysis of association between novel IBD-associated genetic variants and OTUs or genera 
was performed using Phyloseq22 and the DESeq2 algorithm 
(http://www.bioconductor.org/packages/release/bioc/html/DESeq2.html).23 OTUs 
present in less than 10% of samples were removed prior to analysis. An empirical Bayesian 
approach was used to shrink dispersion of normalized count data. Log fold changes for 
each OTU were fitted to a general linear model (fixed effects only) under a negative 
binomial model. Multivariate models included gender, lavage site, disease status, body 
mass index (BMI) (25< or >25), and SLC39A8 carrier status. OTUs or genera were filtered 
out by choosing a mean count threshold maximizing the number of OTUs returned at a 
given false discovery rate. Outliers were replaced by trimmed means, and p-values for the 
coefficients for carrier status in the linear models were calculated using the Wald test, then 
converted to q-values 
(http://www.bioconductor.org/packages/release/bioc/html/qvalue.html). Associations 
were considered significant if they were below a q-value threshold of 0.05. Hypothesis 
inference on the overlap of OTUs associated with CD, obesity and the SLC39A8 Thr391 
allele was performed using the log-linear model. 
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Results	
We analyzed 91,713 rare and common functional (missense, nonsense or splice variant) 
polymorphic SNPs that passed quality control (Table S1). Complete results for all SNPs in 
the single SNP analysis can be found in Table S2. QQ plots show modest genomic inflation 
(λGC=1.074, 1.093 and 1.094 for CD, UC and IBD, respectively). Functional variants in 
previously reported IBD loci such as NOD2, IL23R, and CARD93, 4 were significantly 
associated with CD, UC or both forms of IBD after Bonferroni correction (p<5.45x10-7) 
(Table S3). Furthermore, an additional common missense variant, rs13107325, which 
encodes SLC39A8 Ala391Thr, was significantly associated with CD (p=3.77x10-8; OR=1.31, 
95% CI 1.19-1.44) (Table 1). We also examined the effects of different genotypes of the 
Ala391Thr variant and observed an OR of 1.32, 95% CI 1.19-1.47, for the heterozygous 
Ala/Thr genotype (genotype frequency 16.64% in CD and 13.10% in controls, p=1.66x10-7) 
and an OR of 1.53, 95% CI 0.96-2.36, for the homozygous Thr/Thr genotype (genotype 
frequency 0.92% in CD and 0.63% in controls, p=0.054), suggesting an additive heredity 
model. We checked the conservation of the SLC39A8 Ala391Thr variant across different 
species and observed a PolyPhen24 score of 0.782, indicating that this variant is “possibly 
damaging.” SLC39A8 Ala391Thr has a PHRED score of 18.44 in the Combined Annotation 
Dependent Depletion (CADD) database,25 suggesting that it is among the top 1.43% most 
deleterious substitutions possible in the human genome. 
SLC39A8 is located approximately 200 Kb centromeric from NFKB1, a gene in a known UC-
associated locus, and 250 Kb downstream of BANK1, a gene in a known CD-associated 
locus.3 Conditional analyses were performed by including both index SNPs (rs13126505 in 
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BANK1 and rs1598859 in NFKB1, which has a linkage disequilibrium (LD) r2=1 with the 
reported rs37749593) in the model (Table 1). Effect estimates for SLC39A8 Ala391Thr did 
not vary much (ORcond=1.28, 95% CI 1.12-1.47), although the p-value dropped to 3.00x10-4 
conditional on the two index variants in NFKB1 and BANK1. Interestingly, the effect of the 
known CD-associated BANK1 SNP rs13126505, which is in moderate LD with the SNP 
encoding SLC39A8 Ala391Thr (r2=0.50), greatly diminished in the joint model (in single 
SNP analysis: p=4.43x10-5, OR=1.24; in joint model: p=0.021, OR=1.07). Furthermore, the 
SLC39A8 SNP remained associated with CD in an analysis that was stratified by the BANK1 
SNP (rs13126505), but the BANK1 SNP was no longer significant in the reciprocal 
stratification analysis (Table S4), indicating that the previously identified association signal 
at the BANK1 locus3 is at least partially driven by the SLC39A8 missense variant. The UC-
associated NFKB1 SNP is not in LD with the SNP encoding the CD-associated SLC39A8 
Ala391Thr variant (r2=0.004), strongly suggesting that its effect is independent of the 
observed association with SLC39A8. We also examined the interaction between SLC39A8 
Ala391Thr and known CD SNPs genotyped on the HumanExome+ BeadChip and observed 
no statistically significant interactions after controlling for multiple testing (Table S5). 
We then replicated the SLC39A8 Ala391Thr association in two independent cohorts (Table 
1). We observed similar association in both replication cohorts (pediatric CD GWAS cohort:  
p=2.35x10-3; OR=1.26, 95% CI 1.09-1.46; PRISM cohort: p=1.20x10-4; OR=1.56, 95% CI 
1.24-1.95). The evidence for association between CD and SLC39A8 Ala391Thr was highly 
significant (p=5.55x10-13; OR=1.33, 95% CI 1.21-1.45) in a meta-analysis of the combined 
discovery and replication cohorts. 
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A genotype-subphenotype correlation analysis (Table 2) for SLC39A8 Ala391Thr found 
significant evidence for association with ileal CD (p=0.002 compared to non-ileal CD; 
OR=1.36, 95% CI 1.12-1.66) and with complicated disease behavior (p=0.006 for 
stricturing (B2) or penetrating (B3) vs. non-stricturing, non-penetrating (B1) behavior; 
OR=1.22, 95% CI 1.06-1.40). Joint analysis indicates that the associations of SLC39A8 with 
ileal CD and B2/B3 are independent signals (data not shown).  
Recognizing the role that zinc plays in innate immunity and the pleitropic nature of this 
polymorphism with association with other microbiome associated traits including obesity, 
we hypothesized that the SLC39A8 genetic variant may affect CD susceptibility by altering 
the microbiome. Therefore, we tested the microbial composition of lavage samples from 
the cecum and sigmoid colon of SLC39A8 Thr391 allele carriers and non-carriers in the 
MLI15, 20, 26 cohort. CD patients and healthy controls were analyzed separately and were 
further subdivided by BMI (greater or less than 25) given previous associations of both CD 
and obesity with the microbiome. Carriage of the CD-associated Thr allele was associated 
with altered microbial composition as determined by 16S ribosomal RNA sequencing in 
both healthy controls and CD patients with BMI<25 (p=0.009 and 0.0009, respectively) 
(Figure 1A). We focused on carrier-associated changes in the microbiome of non-
overweight healthy controls to capture pre-disease perturbations that may predispose to 
CD and obesity. A multivariate analysis of the non-overweight healthy controls 
incorporating carrier status, sampling site, and gender revealed statistically significant 
enrichment of 54 OTUs and depletion of 823 OTUs in the Thr allele carriers (Table S6). We 
further investigated whether the microbial signature of non-overweight healthy SLC39A8 
variant carriers resembled that of CD patients. Indeed, 290 of the 823 depleted OTUs 
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reduced in healthy Thr allele carriers were also reduced in non-carrier, non-overweight CD 
patients compared to non-carrier, non-overweight healthy controls, indicating a strongly 
statistically significant overlap (p=9.24x10-16) of the shift in gut microbiota (Figure 1B, 
Table S7). There was similar overlap of the SLC39A8 microbial signature with that of 
individuals with BMI>25: 443 OTUs depleted in non-overweight healthy Thr allele carriers 
were also reduced in overweight, non-IBD, non-carriers (p=6.73x10-16) (Table S8). This 
overlap was not observed in the enriched OTUs (19 and 13 of the 54 enriched OTUs also 
associated with CD and overweight status, with p=0.88 and 0.10, respectively).  
Among relatively abundant bacterial taxa, five genera depleted in SLC39A8 Thr391 allele 
carriers were also significantly (q<0.05) depleted in CD patients and overweight controls 
(Anaerostipes, Coprococcus, Roseburia, Lachnospira, and SMB53) (Figure 1C). Additional 
genera depleted in carriers and CD included Faecalibacterium prausnitzii and Ruminococcus 
gnavus. The most strongly depleted genus in Thr allele carriers was [Eubacterium] 
(q=9x10-10), attributable to reduced abundance of three OTUs identified as E. biforme 
(Figure 1C). Other changes specific to Thr allele carriers included specific species of the 
Bacteroides (e.g., B. eggerthii and B. fragilis), Dorea genera Sutterella, and Collinsella 
aerofaciens.	
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Discussion	
In the current study, we utilized the Illumina ExomeChip to identify functional variants 
associated with IBD. We found that a missense variant in SLC39A8, a pleiotropic locus with 
effects in several phenotypes including hypertension, blood lipid, obesity as well as 
schizophrenia, is associated with CD. We replicated this finding in two independent cohorts 
and illustrated that this locus is also associated with disease location and behavior in CD. 
We further demonstrated that this locus is associated with shifts in the composition of the 
gut microbiota in both CD and controls. Moreover, these SLC39A8-associated shifts in the 
composition of the gut microbiota strongly overlap with gut microbiota changes associated 
with CD and obesity. 
SLC39A8 is part of a family of zinc transporters that is localized to the plasma membrane 
and early endosomes27 and mediates zinc influx into the cytosol.28, 29 Zinc has 
concentration-dependent effects on immune function, and zinc deficiency has been shown 
to affect T cell counts and function.30 SLC39A8 is highly expressed in T cells, stimulated 
monocytes, and differentiated macrophages,28, 31 and a recent study demonstrated that 
continuous stimulation of pattern recognition receptors in macrophage derived monocytes 
increased intracellular zinc concentrations and enhanced macrophage clearance of bacteria 
via autophagy.32 Upregulated expression of SLC39A8 during T cell activation leads to 
increased intracellular zinc in the cytoplasm and increased IFN-γ expression.28 In addition, 
SLC39A8 is upregulated in response to tumor necrosis factor-alpha and lipopolysaccharide 
and serves as a negative regulator of innate immune function and of NF-κB signaling via 
zinc-mediated suppression of IκB kinase in monocytes and macrophages.33, 34 Such effects 
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on T cell function and innate immunity are of potential key pathophysiologic relevance to 
IBD, and our findings highlight the importance of further defining the role of zinc in IBD. In 
a study of treatment naïve pediatric IBD patients, SLC39A8 was one of 1,281 genes that 
were differentially expressed in ileal biopsies from patients with CD.35 SLC39A8 Ala391Thr 
has also been associated with lipid levels, blood pressure, obesity and schizophrenia, 
emphasizing the pleiotropic and critical role of this variant in health and disease as well as 
further highlighting the intriguing relationship among metabolic features, psychiatric 
illness, and chronic inflammation.36-41 
CD, dyslipidemia and obesity have all been linked to alterations in the intestinal 
microbiome,6, 42 and a recent study linked the same gut microbiome change (decrease in 
Akkermansia muciniphila) to both IBD and type II diabetes.43 Furthermore, in a study of the 
microbiome in new-onset CD, an exploratory analysis of genomes of organisms associated 
with CD identified a contribution to pathway components that included a zinc-dependent 
enzyme.6 We therefore hypothesized that the SLC39A8 genetic variant identified in this 
study may affect CD susceptibility by altering the microbiome. In the microbiome analysis, 
5 genera (Anaerostipes, Coprococcus, Roseburia, Lachnospira, and SMB53) are depleted in 
SLC39A8 Thr391 allele carriers, CD patients and overweight controls. Faecalibacterium 
prausnitzii and Ruminococcus gnavus are depleted in both Thr allele carriers and CD. These 
genera (with the exception of SMB53) are notable for being producers of short-chain fatty 
acids, which can ameliorate colitis through induction of regulatory T cells.44, 45 Prior studies 
also found lower levels of Faecalibacterium prausnitzii in IBD,6, 11, 46, 47 and higher levels of 
this bacterium are associated with lower risk of postoperative CD recurrence and 
maintenance of remission in UC.47, 48 An early small Sanger sequencing study of ileal 
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biopsies had suggested increased Ruminococcus gnavus in CD,49 possibly reflecting 
differences in ileal vs. colonic location or differences among Ruminococcus gnavus strains in 
their association with CD. This organism was also depleted in CD patients compared to 
healthy controls, an association not previously reported but perhaps related to the unique 
mucosal lavage sampling protocol used for this cohort. Thus, SLC39A8 is part of an 
emerging set of loci associated with taxonomically-restricted microbial composition.48 
We investigated the effect of SLC39A8 Ala391Thr on protein structure. The closest 
transporters to SLC39A8 are SLC39A14 and SLC39A12 with 50% sequence identity. There 
is no known X-ray 3D structure for SLC39A8, and since this region is not homologous to 
other zinc transporters with X-ray 3D structures, the effect of the Ala391Thr variant on the 
structure of SLC39A8 cannot be inferred. Thus the effect of this variant on transporter 
structure is uncertain. It is notable that the Ala391Thr variant is located in a 
transmembrane domain (based on Uniprot) and mutations involving polar residues are 
particularly associated with protein malfunction.50 Loss of function of SLC39A8, a zinc 
solute transporter, may perturb zinc uptake by epithelial and immune cells and cause zinc 
deficiency as has been observed in SLC39A8 hypomorphic mice.51 Animal studies have 
indicated that zinc deficiency alters microbial function and composition.52 Moreover, some 
ion channels, such as KCNN4, which share membrane transporter properties and roles with 
solute transporters, are activated by intracellular calcium and regulate Paneth cell 
secretion53 with an impact on immune cell and epithelial cell function.54 Therefore, we 
speculate that by disturbing the transmembrane domain of SLC39A8, Ala391Thr may alter 
zinc metabolism in functionally relevant cells, which might in turn affect innate and 
adaptive immunity, as well as the gut microbiota.  
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In summary, we identified and replicated a novel association between CD and SLC39A8, a 
zinc transporter linked to multiple metabolic traits. The SLC39A8 Ala391Thr variant 
identified in our study was associated with altered microbiome composition in both 
healthy controls and CD patients. Moreover, the observed microbe signature in healthy 
SLC39A8 Thr391 allele carriers strongly overlaps with that in CD patients and overweight 
individuals, suggesting a pre-disease microbial susceptibility state originating due to 
genetic influence on the microbial ecosystem that contributes to the pleiotropic effect of 
SLC39A8 in CD and metabolic traits. 
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Figure	1.	SLC39A8	polymorphism	is	associated	with	shifts	in	the	colonic	microbiome	
paralleling	those	of	Crohn’s	disease	and	obesity.	A) Principal coordinates analysis plots 
of the MLI cohort, divided into subsets by CD status and BMI. Individuals are colored by 
SLC39A8 Thr391 allele carrier status. Each PCoA plot shows the number of samples from 
carriers (red) and non-carriers (blue) in the upper left corner and p-values for the 
difference in microbial composition between carriers and non-carriers in the upper right 
corner. B) Venn diagrams depicting the overlap of enriched and depleted OTUs in three 
comparisons: SLC39A8 Thr391 allele carriers vs. non-carriers in the non-CD subset with 
BMI<25, CD vs. non-CD individuals in the non-carrier subset with BMI<25, and BMI>25 vs. 
BMI<25 in the non-carrier, non-CD subset. OTUs were identified as enriched or depleted if 
they had q<0.05 in multivariate models with sample site (cecum, sigmoid) and gender as 
additional covariates. C) Log2 fold changes (FC) for OTUs with a statistically significant 
difference in abundance between carriers and non-carriers from multivariate models. Only 
OTUs identified to the genus level with mean normalized abundance > 10-4 in the non-IBD, 
BMI<25 subset are shown. Colors correspond to the Venn diagrams in panel B. Genera are 
ordered by the log2 fold changes of entire genera between carriers and non-carriers.	
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Table 1. Meta-analysis of the association of SLC39A8 Ala391Thr variant with CD in discovery and replication cohorts 
Gene SNP Cohort N cases N controls FA* FU^ P OR(95% CI) 
  Discovery cohort 5742 5726 0.092 0.072 3.77x10-8 1.31(1.19-1.44) 
SLC39A8 Ala391Thr Pediatric CD GWAS 1096 6088 0.108 0.088 2.35x10-3 1.26(1.09-1.46) 
  PRISM 551 2344 0.109 0.072 1.20x10-4 1.56(1.24-1.95) 
  Meta-analysis 7389 14158 - - 5.55x10-13 1.33(1.21-1.45) 
*FA: Frequencies of Thr allele in CD  
^FU: Frequencies of Thr allele in non-IBD 
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Table 2. Association of SLC39A8 Ala391Thr with clinical phenotypes of CD 
Gene SNP Outcome* N P OR(95% CI) 
      
  B2 vs. B1 3415 0.030 1.20(1.02-1.42) 
 B3 vs. B1 3602 0.012 1.23(1.05-1.45) 
 B3 or B2 vs. B1 4852 0.006 1.22(1.06-1.40) 
      
SLC39A8 Ala391Thr Colonic location 4942 0.966 1.00(0.86-1.17) 
 Ileal location 4823 0.002 1.36(1.12-1.66) 
 Jejunal location 4460 0.205 1.17(0.92-1.50) 
 Perianal disease 4876 0.868 0.99(0.85-1.15) 
      
  Surgery 4841 0.268 1.08(0.94-1.24) 
* Disease behavior classified according to Montreal classification: B1 – inflammatory or non-stricturing/non-internal 
penetrating phenotype; B2 – Stricturing phenotype; B3 – internal penetrating or fistulizing phenotype. 
Surgery is defined as abdominal surgery for complication of Crohn’s disease. 
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